Double-Blind Randomized Placebo-Controlled Cross-Over Phase IIa Trial to Evaluate Efficacy of CVXL-0107 on Parkinson-Related Symptoms and Levodopa-Induced Dyskinesia in Advanced Parkinson's Disease Patients Using a Levodopa Challenge Test
Phase of Trial: Phase II
Latest Information Update: 26 Jul 2017
At a glance
- Drugs EGT-022 (Primary) ; Levodopa
- Indications Parkinson's disease
- Focus Therapeutic Use
- Sponsors CleveXel Pharma
- 20 Jul 2017 Status changed from recruiting to completed.
- 30 Jan 2017 Planned End Date changed from 1 Feb 2017 to 1 Jun 2017.
- 30 Jan 2017 Planned primary completion date changed from 1 Nov 2016 to 1 May 2017.